This study, called CAPS5, is looking for early signs of pancreatic cancer in people who have a higher risk of developing it. Researchers will use Secretin (a drug injected to stimulate pancreatic fluid) and collect this fluid to check for biomarkers (substances that can indicate disease). They will also use MRI (a type of imaging scan) if certain blood test results (CA-19-9) are abnormal, and a special gene test for CA-19-9 to understand individual levels. The study aims to find early cancer markers in pancreatic fluid over 10 years. You might be able to join if you are 18 or older and have conditions like hereditary pancreatitis, Peutz-Jeghers Syndrome, a strong family history of pancreatic cancer, or a confirmed gene mutation (like BRCA1, BRCA2, or Lynch Syndrome).

Study design

This is an interventional study with a planned enrollment of 9000 participants. It is not specified if it's randomized or blinded.

What's involved

You would receive an injection of Secretin, have pancreatic fluid collected, and potentially undergo an MRI abdomen with contrast. A tumor marker gene test for CA19-9 will also be performed.

Compensation

Not stated in the trial record.

Follow-up

The study will evaluate pancreatic juice for early cancer markers over 10 years.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.